L5178Y (LY-R/LY-S) Syngeneic Model Overview
The L5178Y syngeneic model is a murine T-cell lymphoma system derived from DBA/2 mice and has been extensively used in cancer immunology, chemotherapy, and radiobiology research. Two principal sublines of this model—L5178Y-R (radiation-resistant) and L5178Y-S (radiation-sensitive)—enable comparative analysis of treatment response and cellular repair mechanisms. Together, they form one of the most established preclinical systems for investigating immune modulation, DNA damage response, and lymphoma biology.
When implanted subcutaneously or intraperitoneally, L5178Y cells produce rapidly growing tumors with consistent kinetics and predictable morphology. The model’s high reproducibility, distinct sensitivity profiles, and immunocompetent DBA/2 host background make it valuable for evaluating cytotoxic therapies, immune checkpoint inhibitors, and radiation-sensitizing agents.
Request a Custom Quote for L5178Y (LY-R/LY-S) Syngeneic ModelBiological and Molecular Characteristics
The L5178Y lymphoma cell line originated from a methylcholanthrene-induced T-cell lymphoma in a DBA/2 mouse. The two major sublines—LY-R and LY-S—differ primarily in their radiation sensitivity and DNA repair capacity. LY-R cells exhibit increased resistance to ionizing radiation and certain chemotherapeutic agents, while LY-S cells are more sensitive due to impaired DNA double-strand break repair mechanisms.
Both sublines display typical T-cell morphology and express surface markers such as Thy1 and CD3. The tumor microenvironment is characterized by high proliferation, immune infiltration, and moderate PD-L1 expression. Cytokines including IL-2, IFN-gamma, and TNF-alpha are upregulated during immune activation, providing a rich platform for assessing immune responses and radiation-immunotherapy interactions.
| Parameter | Description |
|---|---|
| Host strain | DBA/2 (female, 6–8 weeks) |
| Tumor origin | Chemically induced T-cell lymphoma (mouse) |
| Histological type | T-cell lymphoma |
| Inoculation route | Subcutaneous or intraperitoneal |
| Tumor take rate | >95% |
| Doubling time | Approximately 2–3 days in vivo |
| Metastatic potential | Low; localized or disseminated in IP models |
| Immunophenotype | CD3-positive; moderate PD-L1 expression |
| Common applications | Radiobiology, immunotherapy, chemotherapy sensitivity, DNA repair studies |
In Vivo Model Development and Tumorigenicity
The L5178Y model can be established through subcutaneous or intraperitoneal implantation of viable tumor cells into DBA/2 mice. Subcutaneous implantation results in localized solid tumors suitable for measuring growth kinetics and treatment efficacy. Intraperitoneal inoculation generates disseminated lymphoma, which more closely resembles systemic disease. Tumors typically appear within 4–6 days and progress rapidly without intervention.
The distinct LY-R and LY-S sublines enable comparative studies of therapy resistance and radiation-induced immune effects. LY-R tumors are often used for evaluating combination treatments that include immune checkpoint inhibitors and radiation, while LY-S tumors serve as controls for radiation sensitivity and DNA repair studies. This dual-line system provides a powerful tool for mechanistic exploration of tumor resilience and immune modulation.
Request a Custom Quote for L5178Y (LY-R/LY-S) Syngeneic ModelHistopathology and Immunohistochemical Profile
Histological evaluation of L5178Y tumors reveals densely packed lymphoid cells with high nuclear-to-cytoplasmic ratios, prominent nucleoli, and frequent mitotic figures. In subcutaneous models, the tumors form solid sheets of malignant T cells infiltrating adjacent connective tissue. Intraperitoneal models show disseminated involvement of peritoneal surfaces and lymphoid organs.
Immunohistochemical staining demonstrates strong CD3 and Thy1 expression, confirming T-cell lineage, and high Ki-67 staining indicative of rapid proliferation. PD-L1 expression is moderate and can be upregulated following exposure to cytokines or radiation. F4/80 and CD11b staining identify macrophage and myeloid cell infiltration, reflecting an active but immunosuppressed tumor microenvironment. These histological features replicate the characteristics of aggressive T-cell lymphoma and provide a reliable context for immunotherapy and DNA repair research.
Preclinical Applications and Drug Response
The L5178Y (LY-R/LY-S) syngeneic model is a classic system for studying tumor radiosensitivity, chemotherapeutic efficacy, and immune response dynamics. LY-R tumors are resistant to radiation and certain cytotoxic drugs such as alkylating agents, while LY-S tumors display significant sensitivity, making them ideal for differential drug response evaluation. Both sublines have been widely used in studies of DNA repair inhibitors, immune checkpoint blockade, and combination therapies integrating immunotherapy with radiation.
This model has also been instrumental in evaluating cytokine-based treatments, adoptive T-cell therapy, and radioprotective agents. Its predictable growth, immunocompetent setting, and established molecular profiles make L5178Y one of the most enduring and versatile murine lymphoma models for translational oncology and radiobiology.
Request This Model
To request the L5178Y (LY-R/LY-S) syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for L5178Y (LY-R/LY-S) Syngeneic Model